4 completed, 3 terminated. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 3 |
| Phase 2 | 1 | Completed 1 |
Follow Iodine-131: new trials by email Literature Review of Iodine-131 trials Research Report on Iodine-131
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery pazopanib hydrochloride, iodine I 131 - Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 1 | Completed | University of Washington | 6 | 2011-12-01 | 2015-11-05 |
| Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 16 | 2009-02-01 | 2020-04-03 |
| Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction - Prostate Cancer | Phase 1 | Terminated | Mayo Clinic | 8 | 2008-11-03 | 2026-07-22 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 26 | 2007-10-05 | 2023-02-09 |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma | Phase 1 / Phase 2 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2007-04-01 | 2016-07-13 |
| Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma 131 I-iodine (131-I), 124 I-iodine (124-I) - Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 20 | 2005-03-07 | 2025-10-09 |
| Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer azacitidine, liothyronine sodium, iodine I 131 - Head and Neck Cancer | Phase 1 | Completed | Lucille P. Markey Cancer Center at University of Kentucky | 1999-07-01 | 2013-12-19 |
Thyroid Neoplasms (3) · Adenocarcinoma, Follicular (2) · Thyroid Cancer, Papillary (2) · Anemia, Refractory, with Excess of Blasts (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Neuroendocrine Tumors (1) · Paraganglioma (1) · Pheochromocytoma (1) · Prostatic Neoplasms (1) · Thyroid Diseases (1)
Fred Hutchinson Cancer Center (2) · Lucille P. Markey Cancer Center at University of Kentucky (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Molecular Insight Pharmaceuticals, Inc. (1) · University of Washington (1)
United States (7)
Ajay Gopal (1) · Brian J. Davis, M.D. (1) · Johnnie Orozco (1) · Kenneth Ain, MD (1) · Laura Chow (1) · Ravinder Grewal, MD (1)
PMID 28662033, PMID 29099942, PMID 37939122
P01CA044991 (2), P30CA015704 (2), P50CA091956 (1)